Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment

Investig Clin Urol. 2023 Sep;64(5):419-421. doi: 10.4111/icu.20230185.

Authors

Minyong Kang^{1

2

3}, Seong Soo Jeon⁴

Affiliations

¹ Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
³ Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
⁴ Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. seongsoojeon@gmail.com.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
Prostatic Neoplasms* / drug therapy

Substances

Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors